Gonadotropin-Releasing Hormone Receptor (GnRHR) Elagolix Sodium 832720-36-2  

Elagolix Sodium CAS number is 832720-36-2, an oral gonadotropin-releasing hormone receptor antagonist, ultimately reduces blood levels of gonadal hormones by inhibiting the pituitary gland gonadotropin releasing hormone receptor. Elagolix Sodium was developed jointly by AbbVie and Neurocrine Biosciences. Aberdeen submitted the drug's NDA in September 2017, and was granted FDA priority review after more than one month, and was approved by the FDA on July 23, 2018 under the trade name Orilissa for therapeutic purposes. The pain caused by endometriosis and the first new oral drug for such indications in more than 10 years. Currently, Aberdeen is investigating the treatment of some sex hormone-mediated diseases such as uterine fibroids and endometriosis. So far, more than 40 clinical trials have been conducted, involving more than 3,000 patients. In addition, Phase III clinical trials of dysprosium in the treatment of uterine fibroids are also underway, with great market prospe…